Revised intimation of Change in Management with minor correction in the cover letter
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals' Board of Directors meeting on May 5, 2026 approved the re-appointment of two key directors, subject to shareholder approval. Dr. Mukund Gurjar is re-appointed as Whole-time Director for 1 year from August 28, 2026. Mr. Satish Mehta, the Managing Director and CEO, is re-appointed for a further 5 years from April 1, 2027. Both are existing directors with long tenures — Dr. Gurjar has been with the company since 2001 and Mr. Mehta founded the company in 1981. The filing notes this is a revised intimation with a minor correction to the cover letter. A notable governance disclosure reveals that Mr. Satish Mehta is the father of two other Whole-time Directors — Mr. Samit Mehta and Mrs. Namita Thapar — indicating a significant family concentration on the board.
The re-appointments ensure continuity in leadership but the disclosure of familial ties among multiple Whole-time Directors highlights a concentration of family control that may raise governance concerns for institutional investors.